About Contact

Menu
  • Membership
    • Become A Member
    • Our Sponsors
    • Benefits of Membership
    • LifeSciences BC Members Alphabetical
    • LifeSciences BC Members by Sector
    • LifeSciences BC Membership Benefits Program
  • Events & Programs
    • Calendar
    • Past Events
    • Professional / Educational Programs
  • News
    • Member Announcements
    • Industry News
    • Lifescience BC Publications
    • Industry Publications
  • Policy
    • LifeSciences BC Policies
    • Government Relations
    • Industry Policies
    • Policy Papers
  • Resources
    • Government
    • Industry
    • Business – Finance
    • Research
    • Academic
  • Job Board
    • Job Board
    • Frequently Asked Questions
  • Covid 19
    Resources
News
  • Member Announcements
    • CDRD Partners with Université de Sherbrooke to Leverage R&D Expertise in BC and Quebec
    • Celator ® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
    • New BC Showcase launched in portal for Canadian clinical research capabilities Database will help Canada regain its position as a leading competitive nation for clinical trials
    • Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
    • Celator ® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
    • CDRD Partners with Universite de Sherbrooke to Leverage R&D Expertise in BC and Quebec
    • SOHO Biotech Inc. to Participate in 2015 Medical Device Mission to Taiwan
    • Austin Wang, Grade 11 Student from Vancouver, Recognized for Environmental Biotech
    • DelMar Pharmaceuticals Invited to Present at The World NSCLC Summit on June 23-24, 2015
    • ProNAi Therapeutics Files Registration Statement for Proposed Initial Public Offering
    • STEMCELL Technologies Named Company of the Year by BIOTECanada
    • Qu Biologics Appoints Jim Pankovich as Vice President, Clinical Operations and Drug Development
    • JOSEPH GARCIA RECOGNIZED AS A VISIONARY LEADER IN BIOTECANADA’S 2015 GOLD LEAF AWARDS
    • Vancouver Company Wins Prestigious National Award
    • Mapping BC’s Path to Personalized Medicine Global experts discuss and recommend best practices for the integration of personalized medicine into healthcare
    • RepliCel Life Sciences Announces Participation in 23rd World Congress of Dermatology, Vancouver, BC
    • Sirona-Biochem-Corp.-2015-06-03_141817.aspx
    • Xenon Pharmaceuticals To Provide Business and Milestone Update at Jefferies 2015 Global Healthcare Conference
    • Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole
    • Aquinox Pharmaceuticals to Present at 2015 Jefferies Global Healthcare Conference
    • Charles Garcia joins StarFish Medical as new Vice President, Business Development
    • Xenon Pharmaceuticals Appoints Steven Gannon to its Board of Directors
    • Access to New Medicines in Public Drug Plans: Canada and Comparable Countries Report
    • RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference
    • Sirona-Biochem-Corp.-2015-05-20_083407.aspx
    • Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
    • Aquinox Pharmaceuticals Announces First Quarter 2015 Financial Results
    • Qu Biologics Granted European Patent for Use of Bacterial Compositions for the Treatment of Cancer
    • ANNOUNCEMENT OF 2015 AWARD WINNERS First Annual MDDC Awards for Excellence in Biomedical Engineering
    • (MSI) Completes Recruitment of Phase 2 Trial for its Novel Treatment STRADAâ„¢ for Major Depressive Disorder (MDD)
    • Majority of Canadians unprepared for an allergy emergency. Team Allerject educates to save lives
    • Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 KINSHIP Trial of AQX-1125 in Atopic Dermatitis
    • More Federal Wage Subsidies Announced for Canadian Biotech Students
    • AEQUUS AND CORIUM ENTER INTO PRODUCT DEVELOPMENT COLLABORATION FOCUSED ON CNS
    • Aquinox Pharmaceuticals to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference
    • Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto for Crohn’s Disease Clinical Trial
    • Biolux-Research-Ltd.-2015-04-23_105217.aspx
    • National Access Project for Cancer Testing Gains Momentum
    • SOHO Biotech Inc. to Release Histamine Elisa Kits for Testing Fish Poisoning
    • RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis
    • Aquinox Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference
    • Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (PHN)
    • Biolux-Research-Ltd.-2015-04-01_115834.aspx
    • Qu Biologics Granted U.S. Patent for Use of E. coli to Treat Crohn’s Disease
    • Northview-Ventures-2015-03-27_100217.aspx
    • Tekmira Presents Preclinical Results Demonstrating Super-Additive Effects on Plasma Triglyceride Lowering by Silencing of ApoC3 and ANGPTL3 Genes
    • Qu Biologics Begins Research Collaboration with the University of Rochester, New York
    • RepliCel Life Sciences Meets with Japanese Pharmaceutical and Medical Devices Agency (PMDA)
    • SORIN GROUP SIGNS MERGER AGREEMENT WITH CYBERONICS
    • Aequus-Pharmaceuticals-2015-03-17_063918.aspx
    • Aequus Pharmaceuticals Lists on the TSX Venture Exchange and Appoints New Director
    • XENON PHARMACEUTICALS APPOINTS DR. RICHARD H. SCHELLER TO ITS BOARD OF DIRECTORS
    • Aquinox Pharmaceuticals Announces Year End 2014 Financial Results
    • RepliCel Life Sciences in Japan for Key Industry Meetings
    • XENON PHARMACEUTICALS REPORTS 2014 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
    • Response Biomedical Corp. Schedules Fourth Quarter and Fiscal Year 2014 Earnings Release and Conference Call
    • Member Announcements">Aquinox Pharmaceuticals to Announce Year End 2014 Financial Results and Host Conference Call on March 16, 2015

      Member Announcements

    • Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2014 Financial Results and Provide Corporate Update
    • Biolux-Research-Ltd.-2015-03-06_104449.aspx
    • Sirona-Biochem-Corp.-2015-03-04_080855.aspx
    • Qu Biologics Named Life Sciences BC Growth Stage Company of the Year
    • Contextual Genomics and the Personalized Medicine Initiative Welcome Pfizer Canada to Consortium for National Access Project for Cancer Testing
    • 17th Annual LifeSciences BC 2015 Award Winners, presented by FARRIS
    • Patented Canadian Technology that Measures Heart Rate and Blood Oxygen Levels through Smartphones and Other Mobile Devices Approved by Health Canada
    • LGTmedical Announces Issuance of U.S. Patent for Kenek Coreâ„¢ Audio Waveform Technology
    • Aquinox Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference
    • Aequus Pharmaceuticals Becomes Reporting Isuuer
    • XENON PHARMACEUTICALS’ PARTNER TEVA TO INITIATE PHASE 2b CLINICAL TRIAL OF TV-45070 IN POST-HERPETIC NEURALGIA
    • NSERC Brockhouse Canada Prize Honours Medical Isotope Team CycloMed99
    • Response Biomedical Corp. Announces Milestone Achievement in Co-Development Collaboration
    • Northern Lipids Inc is pleased to announce the appointment of Dr. Norbert Maurer as Director of R&D
    • Global News – B.C. company providing free genomics cancer test to 2000 Canadians
    • Contextual Genomics and the Personalized Medicine Initiative Receive Funding from AstraZeneca for National Access Project for Cancer Testing
    • Notice of Upcoming Funding Opportunity 2015 Large-Scale Applied Research Project Competition Natural Resources and the Environment: Sector Challenges – Genomic Solutions
    • Zymeworks Announces Bi-Specific Antibody Collaboration with Celgene
    • Interprovincial collaboration launched to advance clinical research
    • RepliCel Life Sciences to Present at Biotech Showcase 2015 in San Francisco
    • Canadian Team Demonstrates Solution to Medical Isotope Crisis
    • Pfizer Acquires Redvax GmbH
    • Member Announcement
    • Lilly Finalizes Novartis Animal Health Acquisition
    • RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement
    • Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
    • Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
    • Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
  • Industry News
    • 2016
    • 2015
    • 2014
  • Lifescience BC Publications
    • BioLinks
  • Industry Publications

Sign Up For Our Newsletter

Biolinks: A Twice-Weekly Snapshot of What's Happening in The Life Sciences Community

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: LifeSciences BC, 1890 - 1066 West Hastings St.,, Vancouver, V6E 3X2, https://www.lifesciencesbc.ca. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Life Sciences in British Columbia: Sector Profile – June 2020

Putting Innovation to Work for British Columbia: Growing B.C. Companies

Innovation Commissioner – Observations on Innovation in BC

HBEST Report

LifeSigns-2018

Roadmap 2.0 “The Time is Now for Personalized Medicine in British Columbia” Personalized Medicine Summit June 2017

A Digital Transformation in Health (Microsoft eBook)

perspective

 

Paving the Way: IEP Labour Market Report 2017

perspective Convergence in Canadian Health and Life Sciences
perspective Life Sciences Report
Gyb-pwc Grow Your Business Innovation Imperative & Keeping Your Business Relevant
   
securing_new_drugs Securing new drugs for future generations: the pipeline of antibiotics The review on antimicrobial resistance chaired by Jim O’Neill May 2015
pulse Pulse of the Industry – Medical Technology Report 2015
moving_beyond Moving Beyond the Boundaries – Connecting and Advancing Women in Biotechnology

 

STAY CONNECTED

b a j r x

ABOUT LSBC

  • Board of Directors
  • Management and Board of Directors
  • Our Sponsors
  • Vision and Mission
  • About the Industry

Membership

  • Become A Member
  • Benefits of Membership
  • LifeSciences BC Members Alphabetical
  • LifeSciences BC Members by Sector
  • LifeSciences BC Membership Benefits Program

EVENTS

  • Event Calendar
  • Past Events
  • Professional / Educational Programs
  • Newsletter Sign Up

News

  • Member Announcements
  • Industry News
  • Lifescience BC Publications
  • news
  • member announcements

Employment

  • Jobs Board
  • Frequently Asked Questions

Resources

  • Government
  • Industry
  • Business – Finance
  • Research
  • Academic

CONTACT US

p: 604-669-9909

e: info@lifesciencesbc.ca

© 2021
Privacy Policy